Stock STAB STATERA BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Statera Biopharma, Inc. Stock Nasdaq

Equities

STAB

US8575611046

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 02:24:07 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.0007 USD 0.00% Intraday chart for Statera Biopharma, Inc. 0.00% -99.98%
2023 Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. CI
2023 Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index CI

Financials (USD)

Sales 2020 - Sales 2021 1.49 Capitalization 73.82M
Net income 2020 -12M Net income 2021 -102M EV / Sales 2020 * -
Net Debt 2020 1.41M Net Debt 2021 14.28M EV / Sales 2021 59,246,379 x
P/E ratio 2020 *
-
P/E ratio 2021
-0.79 x
Employees 46
Yield 2020 *
-
Yield 2021
-
Free-Float 100%
More Fundamentals * Assessed data

Chart Statera Biopharma, Inc.

Dynamic Chart

Latest news about Statera Biopharma, Inc.

Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs. CI
Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index CI
Statera Biopharma, Inc.(OTCPK:STAB) dropped from NASDAQ Composite Index CI
Statera Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Statera Biopharma, Inc. announced that it has received $0.4 million in funding from Silverback Capital Corporation CI
Statera Biopharma, Inc. announced that it expects to receive $0.765 million in funding CI
Statera Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Statera Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
US Futures Lower Amid Earnings Reports, Ahead of Flash PMI Data MT
Top Premarket Gainers MT
Top Premarket Decliners MT
Statera Biopharma, Inc. entered a Binding Memorandum of Understanding to acquire 25% in Holobeam Technologies, Inc. for $25 million. CI
Top Premarket Decliners MT
Wall Street Set to Open Lower as Jobless Claims Rise MT
US Futures Lower as Prices Fuel Investors' Inflation Concerns MT
More news

Press releases Statera Biopharma, Inc.

STATERA BIOPHARMA, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K) AQ
STATERA BIOPHARMA, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K) AQ
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K) AQ
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) AQ
Statera Biopharma : Material Agreement - Form 8-K PU
More press releases

Quotes and Performance

Current month-99.98%
Current year-99.98%
More quotes

Highs and lows

3 years
0.00
Extreme 0.0007
7.10
5 years
0.00
Extreme 0.0007
10.97
10 years
0.00
Extreme 0.0007
13.80
More quotes

Managers and Directors - Statera Biopharma, Inc.

Managers TitleAgeSince
Yakov Kogan FOU
 Founder 50 03-06-04
Andrei V. Gudkov FOU
 Founder 66 03-06-04
Michael Handley CEO
 Chief Executive Officer 52 21-07-26
Members of the board TitleAgeSince
John A. Kallassy BRD
 Director/Board Member 59 22-09-01
Uday Saxena BRD
 Director/Board Member 66 22-06-16
Michael Handley CEO
 Chief Executive Officer 52 21-07-26
More insiders

Quotes

Date Price Change Volume
24-04-26 0.0007 0.00% 401
24-04-25 0.0007 0.00% 531
24-04-24 0.0007 0.00% 5,001
24-04-23 0.0007 0.00% 8,810
24-04-22 0.0007 0.00% 21,109

Delayed Quote Nasdaq, April 26, 2024 at 02:24 pm EDT

More quotes

Company Profile

Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. It has platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. The Company is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.59B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 40.65B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 40.57B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 24.81B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.17B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.7B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11.1B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. STAB Stock
  4. STAB Stock